![[LEFT] séparateur](/var/pcr/storage/images/pcronline/left-separateur/3272995-12-eng-GB/LEFT-separateur.png "[LEFT] séparateur"){kind=small}
![[LEFT] séparateur](/var/pcr/storage/images/pcronline/left-separateur3/3273263-12-eng-GB/LEFT-separateur.png "[LEFT] séparateur"){kind=small}
![[LEFT] séparateur](/var/pcr/storage/images/pcronline/left-separateur5/3273349-12-eng-GB/LEFT-separateur.png "[LEFT] séparateur"){kind=small}
![[LEFT] séparateur](/var/pcr/storage/images/pcronline/left-separateur4/3273295-12-eng-GB/LEFT-separateur.png "[LEFT] séparateur"){kind=small}
![[LEFT] séparateur](/var/pcr/storage/images/pcronline/left-separateur2/3273011-12-eng-GB/LEFT-separateur.png "[LEFT] séparateur"){kind=small}
![[LEFT] séparateur](/var/pcr/storage/images/pcronline/left-separateur7/3273451-12-eng-GB/LEFT-separateur.png "[LEFT] séparateur"){kind=small}
![[LEFT] séparateur](/var/pcr/storage/images/pcronline/left-separateur8/3273011-12-eng-GB/LEFT-separateur.png "[LEFT] séparateur"){kind=small}
![[LEFT] séparateur](/var/pcr/storage/images/pcronline/left-separateur9/3273011-12-eng-GB/LEFT-separateur.png "[LEFT] séparateur"){kind=small}
![[LEFT] séparateur](/var/pcr/storage/images/pcronline/left-separateur10/3273365-12-eng-GB/LEFT-separateur.png "[LEFT] séparateur"){kind=small}
![[LEFT] séparateur](/var/pcr/storage/images/pcronline/left-separateur6/3273365-12-eng-GB/LEFT-separateur.png "[LEFT] séparateur"){kind=small}
![[LEFT] séparateur](/var/pcr/storage/images/pcronline/left-separateur11/3273263-12-eng-GB/LEFT-separateur.png "[LEFT] séparateur"){kind=small}
![[LEFT] séparateur](/var/pcr/storage/images/pcronline/left-separateur12/3272995-12-eng-GB/LEFT-separateur.png "[LEFT] séparateur"){kind=small}
- MVD and primary PCI: which strategy?
- 'The Great Debate' - Dual antiplatelet therapy - Which drug? For which patient? For which stent? For how long?
- 'The Great Debate' - Diffuse Coronary artery disease - Available options? New strategies on the Horizon? How to best optimise the options?
- Is what you see really what you get?
- FFR assessment of coronary stenoses in series
- View more...
![[LEFT] Linked in](/var/pcr/storage/images/pcronline/left-linked-in/2103890-3-eng-GB/LEFT-Linked-in.png "[LEFT] Linked in")
Unresolved issues and outlook - Clinical success and new devices
- Main session: All you need to know about renal denervation
- Speaker: Felix MAHFOUD
-
Classification:
Interventions for hypertension & heart failure
- Clinical presentation: Resistant hypertension
- Specific "risks" subset: Diabetes , Metabolic syndrome , Renal insufficiency
- Anatomy subset: Hypertrophic cardiomyopathy
- Sub anatomy subset: Miscellaneous
- Access: Femoral
- Specific technique/treatment: Renal sympathetic denervation
- Complication: No complication
